UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 97

Sortiert nach

First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial

Molecular therapy, 2019-11, Vol.27 (11), p.1930-1938

2019

Volltextzugriff (PDF)

Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models

Scientific reports, 2017-05, Vol.7 (1), p.2396-10, Article 2396

2017

Volltextzugriff (PDF)

Inconsistencies in Modeling the Efficacy of the Oncolytic Virus HSV1716 Reveal Potential Predictive Biomarkers for Tolerability

Frontiers in molecular biosciences, 2022-06, Vol.9, p.889395-889395

2022

Volltextzugriff (PDF)

HSV1716 Prevents Myeloma Cell Regrowth When Combined with Bortezomib In Vitro and Significantly Reduces Systemic Tumor Growth in Mouse Models

Viruses, 2023-02, Vol.15 (3), p.603

2023

Volltextzugriff (PDF)

TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma

Molecular therapy. Oncolytics, 2017-12, Vol.7, p.17-26

2017

Volltextzugriff (PDF)

High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy

Viruses, 2018-03, Vol.10 (3), p.132

2018

Volltextzugriff (PDF)

Macrophage Delivered HSV1716 Is Active against Triple Negative Breast Cancer

Future pharmacology, 2022-12, Vol.2 (4), p.444-459

2022

Volltextzugriff (PDF)

Herpes Simplex Virus Type 1 Infection Stimulates p38/c-Jun N-terminal Mitogen-activated Protein Kinase Pathways and Activates Transcription Factor AP-1

The Journal of biological chemistry, 1999-02, Vol.274 (8), p.5097-5103

1999

Volltextzugriff (PDF)

Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma

iScience, 2021-07, Vol.24 (7), p.102759-102759, Article 102759

2021

Volltextzugriff (PDF)

Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion

Molecular therapy. Oncolytics, 2017-06, Vol.5 (C), p.75-86

2017

Volltextzugriff (PDF)

Tolerance to Self Gangliosides Is the Major Factor Restricting the Antibody Response to Lipopolysaccharide Core Oligosaccharides in Campylobacter jejuni Strains Associated with Guillain-Barré Syndrome

Infection and Immunity, 2002-09, Vol.70 (9), p.5008-5018

2002

Volltextzugriff (PDF)

Retraction for Zachos et al., “Herpes Simplex Virus Type 1 Blocks the Apoptotic Host Cell Defense Mechanisms That Target Bcl-2 and Manipulates Activation of p38 Mitogen-Activated Protein Kinase to Improve Viral Replication”

Journal of virology, 2022-09, Vol.96 (18), p.e0104422-e0104422

2022

Volltextzugriff (PDF)

Herpes Simplex Virus Type 1 Blocks the Apoptotic Host Cell Defense Mechanisms That Target Bcl-2 and Manipulates Activation of p38 Mitogen-Activated Protein Kinase To Improve Viral Replication

Journal of Virology, 2001-03, Vol.75 (6), p.2710-2728

2001

Volltextzugriff (PDF)

Directing cell therapy to anatomic target sites in vivo with magnetic resonance targeting

Nature communications, 2015-08, Vol.6 (1), p.8009, Article 8009

2015

Volltextzugriff (PDF)

Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients

Clinical cancer research, 2017-07, Vol.23 (14), p.3566-3574

2017

Volltextzugriff (PDF)

Herpes Simplex Virus Type 1 Strain HSV1716 Grown in Baby Hamster Kidney Cells Has Altered Tropism for Nonpermissive Chinese Hamster Ovary Cells Compared to HSV1716 Grown in Vero Cells

Journal of Virology, 2005-08, Vol.79 (15), p.9970-9981

2005

Volltextzugriff (PDF)

Abstract 2938: Tumour-associated macrophage polarisation and re-education with oncolytic viruses

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.2938-2938

2017

Volltextzugriff (PDF)

HSV1716 Infects Multiple Myeloma Cells and Leads to CD138 Downregulation

BLOOD, 2022-11, Vol.140 (Supplement 1), p.12440-12441

2022

Volltextzugriff (PDF)

Abstract 2304: Attenuated oncolytic virus HSV1716 increases in vivo expansion of GD2- targeting CAR T cells in murine solid tumor models

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2304-2304

2016

Volltextzugriff (PDF)

Oncolytic herpesvirus therapy for mesothelioma – A phase I/IIa trial of intrapleural administration of HSV1716

Lung cancer (Amsterdam, Netherlands), 2020-12, Vol.150, p.145-151

2020

Volltextzugriff (PDF)

Abstract LB-188: Breast cancer immunotherapy using magnetized HSV1716

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.LB-188-LB-188

2019

Volltextzugriff (PDF)

Nanobugs as Drugs: Bacterial Derived Nanomagnets Enhance Tumor Targeting and Oncolytic Activity of HSV‐1 Virus

Small (Weinheim an der Bergstrasse, Germany), 2022-04, Vol.18 (13), p.e2104763-n/a

2022

Volltextzugriff (PDF)

HSV1716 Prevents Myeloma Cell Regrowth When Combined with Bortezomib IIn Vitro/I and Significantly Reduces Systemic Tumor Growth in Mouse Models

Viruses, 2023-02, Vol.15 (3)

2023

Volltextzugriff (PDF)

Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors

Molecular cancer therapeutics, 2021-03, Vol.20 (3), p.589-601

2021

Volltextzugriff (PDF)

3D co-cultures of epithelial cells with immune cells as a model of HSV and oncolytic HSV infections

Access microbiology, 2020-07, Vol.2 (7A)

2020

Volltextzugriff (PDF)

1 – 25 von 97

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(81)
Mit Volltextzugriff
(86)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(97)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Science & Technology
(51)
Life Sciences & Biomedicine
(47)
Humans
(26)
Animals
(23)
Biological And Medical Sciences
(16)
Female
(15)
Male
(15)
Mice
(15)
Tumors
(11)
Virology
(10)
Fundamental And Applied Biological Sciences. Psychology
(9)
Herpes Simplex Virus 1
(9)
Oncology
(9)
Oncolysis
(9)
Herpes Simplex
(8)
Molecular Sequence Data
(8)
Oncolytic Virus
(8)
Adult
(7)
Cancer
(7)
Immunotherapy
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial

Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models

Inconsistencies in Modeling the Efficacy of the Oncolytic Virus HSV1716 Reveal Potential Predictive Biomarkers for Tolerability

HSV1716 Prevents Myeloma Cell Regrowth When Combined with Bortezomib In Vitro and Significantly Reduces Systemic Tumor Growth in Mouse Models

TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma

High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy

Macrophage Delivered HSV1716 Is Active against Triple Negative Breast Cancer

Herpes Simplex Virus Type 1 Infection Stimulates p38/c-Jun N-terminal Mitogen-activated Protein Kinase Pathways and Activates Transcription Factor AP-1

Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma

Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion

Tolerance to Self Gangliosides Is the Major Factor Restricting the Antibody Response to Lipopolysaccharide Core Oligosaccharides in Campylobacter jejuni Strains Associated with Guillain-Barré Syndrome

Retraction for Zachos et al., “Herpes Simplex Virus Type 1 Blocks the Apoptotic Host Cell Defense Mechanisms That Target Bcl-2 and Manipulates Activation of p38 Mitogen-Activated Protein Kinase to Improve Viral Replication”

Herpes Simplex Virus Type 1 Blocks the Apoptotic Host Cell Defense Mechanisms That Target Bcl-2 and Manipulates Activation of p38 Mitogen-Activated Protein Kinase To Improve Viral Replication

Directing cell therapy to anatomic target sites in vivo with magnetic resonance targeting

Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients

Herpes Simplex Virus Type 1 Strain HSV1716 Grown in Baby Hamster Kidney Cells Has Altered Tropism for Nonpermissive Chinese Hamster Ovary Cells Compared to HSV1716 Grown in Vero Cells

Abstract 2938: Tumour-associated macrophage polarisation and re-education with oncolytic viruses

HSV1716 Infects Multiple Myeloma Cells and Leads to CD138 Downregulation

Abstract 2304: Attenuated oncolytic virus HSV1716 increases in vivo expansion of GD2- targeting CAR T cells in murine solid tumor models

Oncolytic herpesvirus therapy for mesothelioma – A phase I/IIa trial of intrapleural administration of HSV1716

Abstract LB-188: Breast cancer immunotherapy using magnetized HSV1716

Nanobugs as Drugs: Bacterial Derived Nanomagnets Enhance Tumor Targeting and Oncolytic Activity of HSV‐1 Virus

HSV1716 Prevents Myeloma Cell Regrowth When Combined with Bortezomib IIn Vitro/I and Significantly Reduces Systemic Tumor Growth in Mouse Models

Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors

3D co-cultures of epithelial cells with immune cells as a model of HSV and oncolytic HSV infections

Suchergebnisse filtern